Abstract
Background Multiple sclerosis (MS) lesions typically form around a central vein that can be visualized with FLAIR* MRI, creating the central vein sign (CVS) which may reflect lesion pathophysiology. Herein we used Gradient Echo Plural Contrast Imaging (GEPCI) MRI to simultaneously visualize CVS and measure tissue damage in MS lesions. We examined CVS in relation to tissue integrity in white matter (WM) lesions and among MS subtypes.
Subjects and Methods Thirty relapsing–remitting MS (RRMS) subjects and 38 progressive MS (PMS) subjects were scanned with GEPCI protocol. GEPCI T2*-SWI images were generated to visualize CVS. Two investigators independently evaluated WM lesions for CVS and measured lesion volumes. To estimate tissue damage severity, total lesion volume, mean lesion volume, R2t*-based tissue damage score (TDS) of individual lesions and tissue damage load (TDL) were measured for CVS+, CVS-, and confluent lesions. Spearman correlations were made between MRI and clinical data. A paired t-test was used to compare measurements of CVS+ versus CVS- lesions in each individual.
Results 398 of 548 lesions meeting inclusion criteria showed CVS. Most patients had ≥ 40% CVS+ lesions. CVS+ lesions were present in similar proportion among MS subtypes. Interobserver agreement was high for CVS detection. CVS+ and confluent lesions had higher average and total volumes versus CVS- lesions. CVS+ and confluent lesions had more tissue damage than CVS- lesions based on TDL and mean TDS.
Conclusion CVS occurred in RRMS and PMS in similar proportions. CVS+ lesions had greater tissue damage and larger size than CVS- lesions.
Competing Interest Statement
Anne H. Cross is funded by the Manny & Rosenthal, Dr. John L. Trotter MS Center Chair of Barnes Jewish Hospital Foundation and the Leon and Harriet Felman Fund for Human MS Research. She has also received consulting and/or speaking fees from Biogen, Celgene, EMD Serono, Genentech/Roche, Greenwich Biosciences, Janssen Pharmaceuticals, Novartis, and Race to Erase MS, all outside the submitted work.
Funding Statement
This work was supported by the National Institutes of Health [1R25NS090978]; Marilyn Hilton Award for Innovation in MS from the Conrad N. Hilton Foundation; the National MS Society USA [FG 1908 34882]; the National MS Society USA [RG 4463A18]; National Institutes of Health [CO6 RR020092]; NIH/NIA AG054513 and Washington University Institute of Clinical and Translational Sciences Brain, Behavioral and Performance Unit [TR000448]. Anne H. Cross was funded in part by the Manny and Rosalyn Rosenthal, Dr. John L. Trotter MS Center Chair of Barnes-Jewish Hospital Foundation, and the Leon and Harriet Felman Fund for Human MS Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at Washington University in St. Louis, Missouri approved the study (IRB ID #: 201412138). A waiver of consent was obtained to access already acquired clinical data (IRB ID #: 202005043; IRB ID #: 202005044).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: biaoxiang{at}wustl.edu
Email: amber.salter{at}utsouthwestern.edu
Email: yablonskiyd{at}wustl.edu
Email: crossa{at}wustl.edu
↵† Co-senior authors.
Data Availability
Data used in this manuscript will be available upon reasonable request.